Skip to main content
Caplight Logo









Lento Bio, Inc.

Lento Bio, Inc.

Private
Syracuse, New YorkHealthcare & Life Scienceshttps://lentobio.com/

Last Round

Seed

May 30, 2023

Total Funding Raised

$3.58M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Lento Bio, Inc. is a biotechnology company developing small-molecule eyedrops to treat presbyopia by restoring ocular lens flexibility.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologypresbyopia treatmentsmall-molecule therapeuticsophthalmic drugdrug discoveryanti-aging medicineeyedropslongevity biotechclinical trialsprodruginvestigational new drugINDvision correctionpreclinical research

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Lento Bio, Inc. Comparables

Compare Lento Bio, Inc. with similar companies based on industry and business-model similarity.

Lento Bio, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Glaukos Corporation
74%
Novartis
73%
Orasis Pharmaceuticals
70%

Lento Bio, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMay 30, 2023
Pre SeedSep 6, 2022

Key People

Founding team and executive leadership

Kris Barnes

Chief Executive Officer

Executive Team

Lento Bio, Inc. Investors

Notable investors and investment history

Lento Bio, Inc. investors
InvestorRounds
Excell PartnersSeed
Richmond View VenturesPre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors grew 796% MoM, from 68 to 609.

  • May 30, 2023

    $2.9M round led by Excell Partners and Ichor Life Sciences

Lento Bio, Inc. Filings

Explore SEC and related filing metadata, where available.

Lento Bio, Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Lento Bio, Inc.'s valuation, stock price, and market status.

Is Lento Bio, Inc. a public or private company?

Lento Bio, Inc. is a private company.

What is the current stock price of Lento Bio, Inc.?

Lento Bio, Inc. is a private company with no public stock price. No recent secondary market data is available.

How much is Lento Bio, Inc. worth (valuation)?

Valuation information for Lento Bio, Inc. is not publicly available.

Can I buy Lento Bio, Inc. stock?

Lento Bio, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Lento Bio, Inc.'s last funding round?

Lento Bio, Inc.'s most recent funding round was Seed on September 6, 2022.

Who are the main investors in Lento Bio, Inc.?

Key investors in Lento Bio, Inc. include Richmond View Ventures.

Will Lento Bio, Inc. IPO soon?

No public IPO plans have been announced for Lento Bio, Inc..

How can I track Lento Bio, Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Lento Bio, Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSyracuse, New York
Employee Range3
Year Founded2022
Last FundingMay 30, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?